While comments from AdvaMed and the Medical Device Manufacturers Association expressed strong support for a proposal from the Centers for Medicare and Medicaid Services that would allow up to four years of Medicare coverage of Food and Drug Administration-defined breakthrough devices, both groups said commercial insurance coverage decisions should not be used as a template.
Further, both AdvaMed and MDMA want the agency to either back away from defining what should be considered reasonable and...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?